Resiliva is identified on this website as a product containing resmetirom in stated 80 mg and 100 mg strengths. Product-specific manufacturer and regulatory details require verification.

Resmetirom is an oral selective thyroid hormone receptor beta agonist used for specified adults with noncirrhotic MASH/NASH and moderate to advanced liver fibrosis.

The current U.S. indication covers adults with noncirrhotic NASH and F2–F3 fibrosis, together with diet and exercise.

MASH stands for metabolic dysfunction-associated steatohepatitis. It is a form of fatty-liver disease involving liver fat, inflammation and injury.

Resmetirom activates thyroid hormone receptor beta in the liver, influencing pathways involved in lipid metabolism.

The FDA-approved reference product is available in 60 mg, 80 mg and 100 mg tablets. The Resiliva website identifies 80 mg and 100 mg, but Resiliva-specific packaging requires verification.

The current U.S. reference-product regimen is once daily.

Yes, the current U.S. label permits Rezdiffra to be taken with or without food.

Diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain and dizziness are listed among common adverse reactions.

Yes. Hepatotoxicity is an important labeled warning.

Gallbladder-related adverse reactions, including cholelithiasis and cholecystitis, have been reported.

Yes. The U.S. prescribing information contains specific recommendations concerning several statins.

Clopidogrel is a moderate CYP2C8 inhibitor and can require resmetirom dosage modification under the U.S. label.

Current U.S. labeling says to avoid Rezdiffra in patients with decompensated cirrhosis.

Resmetirom was originally developed by VIA Pharmaceuticals under a Roche license; Madrigal Pharmaceuticals subsequently acquired the relevant rights and continued development.

Rezdiffra is the established reference product containing resmetirom.

They should not be described as identical solely because both are identified as containing resmetirom. Product-specific formulation, manufacturer and regulatory information must be established.

No. Resmetirom is a metabolic/liver-directed THR-β agonist rather than a conventional cytotoxic chemotherapy medicine.

No. Regulatory status and approved indications differ by jurisdiction. In the EU, Rezdiffra received conditional marketing authorization in 2025.